TRexBio

South San Francisco, CA · Founded 2018 · Privately Held (backing)

Developer of immunoregulatory medicines designed to restore immune balance in inflammatory diseases through tissue regulatory T cell biology. TRexBio is based in South San Francisco, CA and was founded in 2018. It is valued at about $274 million as of Oct 2026, set by institutional fund marks. It has raised $222 million.

PMV mark · valuation
$274.0M
Oct 2026
Priced at
—
Total raised
$222.1M
Last round
—

Who backs TRexBio?

14 investors
InvestorType
Alexandria Venture InvestmentsOther
Johnson & Johnson JJDCVenture capital
Polaris PartnersVenture capital
SV Health InvestorsVenture capital
Pfizer VenturesOther
Eli Lilly and Company FoundationOther
Balyasny Asset ManagementHedge fund
Laurion Capital ManagementHedge fund
Affinity Asset AdvisorsHedge fund
Agent Capital—
+ 4 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

TRexBio investors

14 investors are on record for TRexBio, including Alexandria Venture Investments, Johnson & Johnson JJDC, Polaris Partners and SV Health Investors. By type, the record holds 3 venture capital firms and 3 hedge funds.

Free account
More of TRexBio with a free account
  • ·The complete investor list: 14 names
  • ·Watch TRexBio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 14 firms already write checks for companies like TRexBio. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View